Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 9/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630294 | 0.84 | CYP1A2 (0.41) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL5828094 | 0.81 | CA12 (0.36) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL5828722 | 0.81 | CYP1A2 (0.35) | CYP1A2ESR1ESR2CA12CA9 | |
| SCHEMBL3952850 | 0.77 | CYP1A2 (0.44) | CYP1A2ESR1ESR2CYP3A4HSD17B10 | |
| SCHEMBL5032964 | 0.77 | MCL1 (0.38) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL28614473 | 0.74 | CYP1A2 (0.46) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL1090982 | 0.71 | CYP1A2 (0.48) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL69484 | 0.71 | CYP1A2 (0.77) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL627219 | 0.71 | CYP1A2 (0.77) | CYP1A2ESR1ESR2CYP3A4ALOX15 | |
| SCHEMBL29364786 | 0.71 | CYP1A2 (0.77) | CYP1A2ESR1ESR2CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883916-A1 | USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES | Momentive Performance Materials GmbH (DE) | 2021-09-29 | — | — | EP | claimed |
| CN-113329993-A | Use of polyhydroxy aromatic compounds for treating fibrous substrates based on amino acids | 迈图高新材料有限责任公司 | 2021-08-31 | — | — | CN | claimed |
| US-20200163850-A1 | USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-05-28 | — | — | US | claimed |
| EP-3883916-A1 | USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES | Momentive Performance Materials GmbH (DE) | 2021-09-29 | — | — | EP | disclosed |
| CN-113329993-A | Use of polyhydroxy aromatic compounds for treating fibrous substrates based on amino acids | 迈图高新材料有限责任公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20200163850-A1 | USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-05-28 | — | — | US | disclosed |
| CN-1276035-C | Water-color ink | MITSUI CHEMICALS INC (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-7025971-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6962791-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6872542-B1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | SIGA PHARMACEUTICALS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| CN-1558934-A | Water-color ink | 三井化学株式会社 | 2004-12-29 | — | — | CN | disclosed |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-10-10 | — | — | US | disclosed |
| US-6420127-B1 | PREVENTION OF MICROORGANISMAL INFECTIONS; OBTAIN MEMBRANES, INCUBATE WITH MODULATORS, MONITOR MICROORGANISMAL INFECTIONS | WASHINGTON UNIVERSITY | 2002-07-16 | — | — | US | disclosed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-03-21 | — | — | US | disclosed |
| US-6153396-A | DRUG SCREENING BY ADDING COMPOUND TO MIXTURE OF CHAPERONE AND PILUS SUBUNIT AND DETERMINING THE CHANGE IN BINDING; BACTERICIDES FOR URINARY TRACT INFECTIONS | SIGA PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6001823-A | NOVEL PYRANOSIDES WHICH ARE BELIEVED TO BE CAPABLE OF INTERACTING WITH PERIPLASMIC MOLECULAR CHAPERONES | WASHINGTON UNIVERSITY | 1999-12-14 | — | — | US | disclosed |
| EP-0730601-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014028-A9 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | — | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014028-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | CYP1A2 3237/4885ESR1 4243/4885ESR2 3355/4885 |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | CYP1A2 3237/4885ESR1 4243/4885ESR2 3355/4885 |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | CYP1A2 3237/4885ESR1 4243/4885ESR2 3355/4885 |
| US-20200163850-A1 | USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES | PAH, CUTA, ASPH | CYP1A2 815/4885ESR1 3231/4885ESR2 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.